13F Holdings
中文EN

TCRT Alaunos Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1107421 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY10.0%
TTM EPS YoY39.1%
Revenue 3-yr CAGR-41.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-121,033.3%
Net margin-120,766.7%
FCF margin—
EBITDA margin-119,966.7%

Returns

ROE-192.0%
ROA-128.4%
ROIC (approx.)-469.9%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio1.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-46.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5,000$10,000$5,000$2.92M$398,000
R&D expense$1.36M$362,000$16.28M$25.02M$49.64M
SG&A expense$2.87M$4.46M$12.22M$13.14M$27.56M
Operating income-$4.22M-$4.81M-$34.27M-$35.10M-$77.55M
Interest expense—$0$1.92M$3.15M$1.19M
Income tax$0————
Net income-$4.18M-$4.68M-$4.68M-$37.73M-$78.75M
EBITDA-$4.22M-$4.81M-$31.95M-$32.35M-$74.95M
EPS (basic)-2.20-2.92-21.97-2.61-0.37
EPS (diluted)-2.20-2.92-21.97-2.61-0.37
Weighted avg. shares (diluted)1.95M1.60M1.60M14.48M214.40M
Balance sheet
Cash & equivalents$1.39M$1.09M$6.06M$53.00M$76.05M
Receivables$3,000$5,000$1,000$4,000$1.11M
Current assets$1.99M$2.75M$8.26M$53.80M$78.83M
PP&E, net$91,000$0$2,000$8.46M$10.94M
Total assets$2.97M$2.75M$8.26M$64.94M$94.86M
Current liabilities$813,000$692,000$1.96M$24.17M$16.04M
Short-term debt——$0$16.77M$7.87M
Long-term debt—$0$0$0$16.25M
Total debt—$0$0$16.77M$24.12M
Total liabilities$813,000$692,000$1.96M$26.38M$36.81M
Shareholders' equity$2.15M$2.06M$6.31M$38.55M$58.06M
Net debt—-$1.09M-$6.06M-$36.23M-$51.94M
Shares outstanding2.35M1.60M1.60M16.03M216.13M
Cash flow statement
Operating cash flow-$2.87M-$4.97M-$30.14M-$29.23M-$61.47M
Capital expenditure$98,000$0$197,000$216,000$3.32M
Free cash flow-$2.97M-$4.97M-$30.34M-$29.45M-$64.79M
Investing cash flow-$98,000$0$1.35M-$193,000-$3.32M
Financing cash flow$3.26M$0-$18.14M$6.37M$25.78M
Depreciation & amortization$7,000$2,000$2.31M$2.76M$2.60M
Stock-based compensation$796,000$435,000$2.80M$3.53M$10.77M
Share buybacks——$0$45,000$0

Free plan shows the latest 5 periods; Pro shows all 22 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.